Positive News SentimentPositive NewsNASDAQ:CMPX Compass Therapeutics (CMPX) Stock Price, News & Analysis $1.08 +0.03 (+2.86%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.00▼$1.1050-Day Range$0.80▼$1.6052-Week Range$0.77▼$3.01Volume640,438 shsAverage Volume413,523 shsMarket Capitalization$148.60 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Compass Therapeutics alerts: Email Address Compass Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside733.3% Upside$9.00 Price TargetShort InterestBearish2.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.39) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.92 out of 5 starsMedical Sector428th out of 936 stocksBiological Products, Except Diagnostic Industry63rd out of 154 stocks 3.5 Analyst's Opinion Consensus RatingCompass Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCompass Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Compass Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.27% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Compass Therapeutics has recently increased by 10.99%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCompass Therapeutics does not currently pay a dividend.Dividend GrowthCompass Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMPX. Previous Next 3.3 News and Social Media Coverage News SentimentCompass Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Compass Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CMPX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Compass Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders30.00% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Compass Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.39) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Therapeutics is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Therapeutics is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompass Therapeutics has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Compass Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.See here to see the full details. About Compass Therapeutics Stock (NASDAQ:CMPX)Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Read More CMPX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMPX Stock News HeadlinesMay 30, 2024 | globenewswire.comCompass Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2024 | globenewswire.comCompass Therapeutics Announces CEO TransitionJuly 27, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.May 23, 2024 | globenewswire.comCompass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024May 14, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Compass Therapeutics (CMPX)May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Compass Therapeutics on Strong Financials and Promising Clinical TrialsMay 14, 2024 | globenewswire.comCompass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 13, 2024 | investorplace.comCMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024July 27, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.May 13, 2024 | globenewswire.comCompass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate UpdateApril 25, 2024 | finance.yahoo.comCompass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously TreatedApril 17, 2024 | benzinga.comCompass Therapeutics Stock (NASDAQ:CMPX), Analyst Ratings, Price Targets, PredictionsApril 12, 2024 | globenewswire.comCompass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual ConferenceApril 11, 2024 | investing.comCompass Therapeutics reports potential in tumor treatmentApril 10, 2024 | finance.yahoo.comCompass Therapeutics to Participate in the Stifel Targeted Oncology DaysApril 10, 2024 | globenewswire.comCompass Therapeutics to Participate in the Stifel Targeted Oncology DaysApril 9, 2024 | globenewswire.comCompass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2024 | markets.businessinsider.comCompass Therapeutics: A Strong Buy on Promising Clinical Pipeline and Strategic MilestonesSee More Headlines Receive CMPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMPX CUSIPN/A CIK1738021 Webwww.compasstherapeutics.com Phone617-500-8099FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+741.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.67% Return on Assets-27.24% Debt Debt-to-Equity RatioN/A Current Ratio40.74 Quick Ratio40.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book0.91Miscellaneous Outstanding Shares137,590,000Free Float96,312,000Market Cap$147.22 million OptionableNot Optionable Beta0.78 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Vered Bisker-Leib M.D. (Age 53)MBA, Ph.D., CEO & Director Comp: $719kDr. Thomas J. Schuetz M.D. (Age 63)Ph.D., Co-Founder, President of Research & Development and Vice Chairman of the Board Comp: $835.88kMr. Neil L. Lerner CPA (Age 57)Vice President of Finance Mr. Jonathan Anderman J.D.VP, Head of Legal & Corporate SecretaryAnna GiffordCommunications ManagerDr. Minori Rosales M.D. (Age 61)Ph.D., Senior VP & Head of Clinical Development Ms. Karin Herrera B.A.VP & Head of Clinical OperationsDr. James Kranz Ph.D.VP and Head of Chemistry Manufacturing & ControlsMore ExecutivesKey CompetitorsPCB BancorpNASDAQ:PCBThird Coast BancsharesNASDAQ:TCBXAnavex Life SciencesNASDAQ:AVXLProKidneyNASDAQ:PROKValnevaNASDAQ:VALNView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 31,433 shares on 7/26/2024Ownership: 0.206%Opaleye Management Inc.Bought 3,170,000 shares on 5/29/2024Ownership: 2.304%Janus Henderson Group PLCSold 54,331 shares on 5/16/2024Ownership: 4.719%CM Management LLCBought 185,000 shares on 5/14/2024Ownership: 0.225%Vanguard Group Inc.Bought 71,008 shares on 5/10/2024Ownership: 3.018%View All Institutional Transactions CMPX Stock Analysis - Frequently Asked Questions How have CMPX shares performed this year? Compass Therapeutics' stock was trading at $1.56 at the beginning of the year. Since then, CMPX shares have decreased by 30.8% and is now trading at $1.08. View the best growth stocks for 2024 here. How were Compass Therapeutics' earnings last quarter? Compass Therapeutics, Inc. (NASDAQ:CMPX) released its quarterly earnings data on Monday, May, 13th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. When did Compass Therapeutics IPO? Compass Therapeutics (CMPX) raised $50 million in an initial public offering on the week of November 16th 2020. The company issued 9,000,000 shares at a price of $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel served as the underwriters for the IPO and Raymond James was co-manager. Who are Compass Therapeutics' major shareholders? Compass Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.21%). Insiders that own company stock include Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib. View institutional ownership trends. How do I buy shares of Compass Therapeutics? Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMPX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMPX Stock Alerts